MITSUBISHI TANABE PHARMA CORPORATION et al v. SANDOZ INC. et al

  1. March 25, 2021

    Mitsubishi Beats Bid To Invalidate Diabetes Drug Patents

    A New Jersey federal judge has refused to invalidate patents for Mitsubishi Tanabe Pharma Corp.'s diabetes drugs Invokana and Invokamet, striking down Zydus Pharmaceuticals Ltd.'s bid to dodge patent infringement claims over its plan to roll out generic versions.

  2. November 25, 2020

    Zydus Insists Mitsubishi Doesn't Deserve Diabetes Patents

    Zydus Pharmaceuticals punctuated the six-day trial in its bid to bring generic diabetes drugs to market by filing a 100-page, post-trial brief doubling down on its claim that Mitsubishi Tanabe Pharma Corp. is engaging in "gamesmanship" to extend the life of one of three patents Zydus is accused of infringing.

  3. November 05, 2020

    Testimony In NJ Zoom Trial Wraps In Diabetes Drug IP Row

    On the last day of trial testimony in Mitsubishi Tanabe Pharma Corp.'s infringement suit that seeks to stop Zydus from bringing generic diabetes drugs to market, Zydus said Thursday "the law is crystal clear" that one of three patents it's accused of infringing is invalid.

  4. May 01, 2020

    COVID-19 IP Catch-Up: Looming Trials, Jeff Dunham's Dummy

    The copyright and patent offices have pushed back certain deadlines as the COVID-19 pandemic continues, while at least one intellectual property bench trial is about to proceed over video. Here, Law360 pulls together all the updates you might have missed, including victories for 3M in its trademark campaign and a new suit by comedian Jeff Dunham seeking to protect his image.

  5. June 07, 2019

    InvaGen Agrees To Admit Infringing Diabetes Drug To End Suit

    Pharmaceutical companies Mitsubishi Tanabe Pharma Corp., Janssen Pharmaceuticals Inc. and Cilag GmbH International have asked a New Jersey federal judge to sign off on their deal to drop a patent infringement lawsuit against InvaGen Pharmaceuticals Inc. over its application for the generic version of Janssen's diabetes treatment Invokamet.